吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

盘后交易 01-16 16:58:21 EST

91.65

-0.73

-0.79%

盘后91.74

+0.09+0.10%

16:54 EST

最高93.07	最低90.82	成交量894.83万
今开92.26	昨收92.38	日振幅2.44%
总市值1,142亿	流通市值1,140亿	总股本12.46亿
成交额8.22亿	换手率0.72%	流通股本12.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":91.65,"timestamp":1737061200000,"preClose":92.38,"halted":0,"volume":8948282,"hourTrading":{"tag":"盘后","latestPrice":91.7399,"preClose":91.65,"latestTime":"16:54 EST","volume":1293394,"amount":118539521.29818,"timestamp":1737064479022},"delay":0,"floatShares":1243810588,"shares":1246265857,"eps":0.097109,"marketStatus":"盘后交易","change":-0.73,"latestTime":"01-16 16:58:21 EST","open":92.26,"high":93.07,"low":90.82,"amount":821900328.07974,"amplitude":0.024356,"askPrice":91.74,"askSize":300,"bidPrice":91,"bidSize":15,"shortable":3,"etf":0,"ttmEps":0.097109,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1737075600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":92.38,"dividendRate":0.033388,"preHourTrading":{"tag":"盘前","latestPrice":92.26,"preClose":92.38,"latestTime":"09:29 EST","volume":632,"amount":58230.309712,"timestamp":1737037799992},"postHourTrading":{"tag":"盘后","latestPrice":91.7399,"preClose":91.65,"latestTime":"16:54 EST","volume":1293394,"amount":118539521.29818,"timestamp":1737064479022},"volumeRatio":1.178961,"optionData":{"bulkOrders":[{"symbol":"GILD","call":true,"expireDate":1737090000000,"strike":"92.5","timestamp":1737042159753,"price":0.75,"volume":1501,"amount":112575,"type":"+"},{"symbol":"GILD","call":true,"expireDate":1737090000000,"strike":"92.5","timestamp":1737042159753,"price":0.75,"volume":1499,"amount":112425,"type":"+"}]},"impliedVol":0.2879,"impliedVolPercentile":0.5873},"requestUrl":"/m/hq/s/GILD","defaultTab":"news","newsList":[{"id":"2504876949","title":"吉利德科学下跌1.22%，报91.25美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2504876949","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504876949?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:34","pubTimestamp":1737052440,"startTime":"0","endTime":"0","summary":"1月17日，吉利德科学(GILD)盘中下跌1.22%，截至02:34，报91.25美元/股，成交3.46亿美元。财务数据显示，截至2024年09月30日，吉利德科学收入总额211.85亿美元，同比增长5.91%；归母净利润-13.03亿美元，同比减少130.76%。大事提醒：2月11日，吉利德科学将于(美东)盘后披露2024财年年报。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2025-01-17/doc-ineffcmm6358942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4566","BK4578","LU0289739699.SGD","BK4585","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1585245621.USD","IE00B3T34201.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","LU2087621335.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU1430594728.SGD","BK4550","LU0889565916.HKD","LU1839511570.USD","BK4139","LU1066051498.USD","IE00B19Z3581.USD","BK4568","LU2468319806.SGD","BK4532","BK4588","LU0234570918.USD","LU0109394709.USD","BK4583","LU0058720904.USD","LU1571399168.USD","GILD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2503814019","title":"吉利德科学与美国政府就艾滋病药物达成10亿美元专利纠纷和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2503814019","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503814019?lang=zh_cn&edition=full","pubTime":"2025-01-16 10:22","pubTimestamp":1736994160,"startTime":"0","endTime":"0","summary":"格隆汇1月16日｜据路透，根据周三提交给特拉华州联邦法院的一份文件，吉利德科学公司与美国政府就吉利德的艾滋病预防药物Truvada和Descovy达成了价值10亿美元的专利纠纷和解。此前，吉利德在2023年的陪审团审判中赢得了有关专利侵权的诉讼。吉利德总法律顾问Deborah Telman在一份声明中表示，该协议“公司继续将资源集中在其使命上，即发现、开发和向患有危及生命疾病的人提供创新疗法。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011610224496055859&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011610224496055859&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0058720904.USD","LU2468319806.SGD","BK4139","BK4583","GILD","IE00B19Z3581.USD","LU0889565916.HKD","BK4588","BK4550","BK4568","LU1066051498.USD","LU1430594728.SGD","IE00BKVL7J92.USD","LU1585245621.USD","LU2087621335.USD","BK4532","IE00B7SZLL34.SGD","BK4585","IE00BSNM7G36.USD","IE0002270589.USD","BK4566","LU0234570918.USD","LU1066053197.SGD","LU0289739699.SGD","LU1571399168.USD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","BK4578","LU1839511570.USD","IE00B3T34201.USD","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2503672802","title":"吉利德科学公司与美国政府就艾滋病预防药物专利案达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2503672802","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503672802?lang=zh_cn&edition=full","pubTime":"2025-01-16 04:40","pubTimestamp":1736973611,"startTime":"0","endTime":"0","summary":"路透1月15日 - 据周三向特拉华州联邦法院提交的一份文件显示，吉利德科学公司GILD.O与美国政府已就吉利德公司的艾滋病预防药物特鲁瓦达和德科威价值数十亿美元的专利纠纷达成和解。此前，吉利德公司  在 2023 年陪审团对政府专利侵权指控的审判中取得了胜利。联邦政府称，吉利德公司未能因发现 Truvada 可以预防 HIV 感染而向 CDC 提供补偿。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nL4T3OB1NB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4578","IE00BSNM7G36.USD","LU0320765992.SGD","LU0058720904.USD","LU1571399168.USD","BK4568","BK4139","LU0234570918.USD","IE00B3T34201.USD","LU2087621335.USD","LU0889565916.HKD","LU2468319806.SGD","BK4532","IE00B19Z3581.USD","LU1066053197.SGD","LU1430594728.SGD","LU1585245621.USD","LU1066051498.USD","BK4585","LU1839511570.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","GILD","LU0109394709.USD","BK4550","IE0002270589.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","BK4583","BK4588","LU0289739699.SGD"],"gpt_icon":1},{"id":"2503647565","title":"吉利德科学上涨1.46%，报92.33美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2503647565","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503647565?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:33","pubTimestamp":1736951580,"startTime":"0","endTime":"0","summary":"1月15日，吉利德科学(GILD)开盘上涨1.46%，截至22:33，报92.33美元/股，成交2460.8万美元。财务数据显示，截至2024年09月30日，吉利德科学收入总额211.85亿美元，同比增长5.91%；归母净利润-13.03亿美元，同比减少130.76%。大事提醒：2月11日，吉利德科学将于(美东)盘后披露2024财年年报。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2025-01-15/doc-inefapww4764691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1430594728.SGD","BK4568","LU0109394709.USD","BK4585","IE0002270589.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","BK4583","BK4566","LU1839511570.USD","LU1571399168.USD","IE00B3T34201.USD","LU2087621335.USD","BK4550","LU1066053197.SGD","BK4139","LU2468319806.SGD","LU0234570918.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4532","LU0889565916.HKD","IE00BSNM7G36.USD","LU1585245621.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0058720904.USD","LU0320765992.SGD","LU1066051498.USD","BK4588","BK4578","GILD"],"gpt_icon":0},{"id":"2503577204","title":"吉利德科学上涨1.26%，报91.07美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2503577204","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503577204?lang=zh_cn&edition=full","pubTime":"2025-01-14 23:32","pubTimestamp":1736868728,"startTime":"0","endTime":"0","summary":"1月14日，吉利德科学(GILD)盘中上涨1.26%，截至23:32，报91.07美元/股，成交8435.66万美元。财务数据显示，截至2024年09月30日，吉利德科学收入总额211.85亿美元，同比增长5.91%；归母净利润-13.03亿美元，同比减少130.76%。大事提醒：2月11日，吉利德科学将于(美东)盘后披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/14233247458135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1066051498.USD","LU2468319806.SGD","LU0289739699.SGD","IE00B3T34201.USD","LU0889565916.HKD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4583","LU1839511570.USD","LU0320765992.SGD","BK4585","LU0109394709.USD","LU0058720904.USD","LU1585245621.USD","IE00BKVL7J92.USD","BK4568","LU1571399168.USD","BK4139","BK4578","BK4566","LU0234570918.USD","IE00BZ1G4Q59.USD","BK4550","LU2087621335.USD","IE00B19Z3B42.SGD","GILD","IE0002270589.USD","IE00BSNM7G36.USD","LU1066053197.SGD","LU1430594728.SGD","BK4532","BK4588"],"gpt_icon":0},{"id":"2503332277","title":"大摩上调吉利德科学目标价至113美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503332277","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503332277?lang=zh_cn&edition=full","pubTime":"2025-01-13 16:14","pubTimestamp":1736756040,"startTime":"0","endTime":"0","summary":"摩根士丹利：将吉利德科学的目标价从87美元上调至113美元，评级从“中性”上调至“增持”。（格隆汇）\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-01-13/doc-ineevkux9533820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GILD"],"gpt_icon":0},{"id":"2503513349","title":"百洋医药：公司没有和吉利德开展品牌运营业务合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2503513349","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503513349?lang=zh_cn&edition=full","pubTime":"2025-01-13 11:33","pubTimestamp":1736739181,"startTime":"0","endTime":"0","summary":"有投资者向百洋医药提问， 媒体报道吉利德HIV长效疗法在华获批，请问公司和吉利德还有合作吗？公司回答表示，投资者您好，公司没有和吉利德开展品牌运营业务合作，谢谢！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113113515aba88ad2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113113515aba88ad2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2468319806.SGD","LU1839511570.USD","LU0234570918.USD","IE00B19Z3581.USD","IE0002270589.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","LU2087621335.USD","LU1585245621.USD","LU1430594728.SGD","LU0320765992.SGD","BK4583","IE00BSNM7G36.USD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066051498.USD","LU1571399168.USD","GILD","LU0289739699.SGD","BK4139","BK4550","BK4568","BK4578","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4585","LU0058720904.USD","BK4532","IE00BZ1G4Q59.USD","LU0109394709.USD","BK4566","BK4588"],"gpt_icon":0},{"id":"2503317532","title":"吉利德科学与LEO Pharma合作开发炎症性疾病项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2503317532","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503317532?lang=zh_cn&edition=full","pubTime":"2025-01-13 10:01","pubTimestamp":1736733696,"startTime":"0","endTime":"0","summary":"格隆汇1月13日｜吉利德科学上周六表示，已与丹麦LEO Pharma达成合作，开发治疗炎症性疾病患者的项目。LEO Pharma将有资格获得高达17亿美元的付款，其中包括吉利德支付的2.5亿美元预付款。作为回报，吉利德将拥有在全球开发、制造和商业化小分子口服 STAT6项目的权利。声明称，针对STAT6的临床前研究已显示出治疗广泛炎症疾病(如特应性皮炎、哮喘和COPD)的潜力。此次交易预计将使吉利德2025年的GAAP和非GAAP每股收益减少约0.15至0.17美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011310015196019293&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011310015196019293&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1066053197.SGD","LU0058720904.USD","BK4585","BK4583","LU1571399168.USD","LU2468319806.SGD","LU1430594728.SGD","BK4566","IE00BKVL7J92.USD","IE00B3T34201.USD","BK4550","LU0320765992.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","LU1839511570.USD","GILD","IE00B19Z3581.USD","LU0234570918.USD","BK4532","LU2087621335.USD","LEO","BK4588","IE00BSNM7G36.USD","BK4568","BK4578","BK4139","IE0002270589.USD","IE00B7SZLL34.SGD","LU1585245621.USD","LU0889565916.HKD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2502883193","title":"吉利德公司与 LEO 制药公司合作开发炎症性疾病项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2502883193","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502883193?lang=zh_cn&edition=full","pubTime":"2025-01-12 01:35","pubTimestamp":1736616917,"startTime":"0","endTime":"0","summary":"    路透1月11日 - 吉利德科学公司周六表示，该公司与丹麦LEOPharma公司建立了合作伙伴关系，共同开发 治疗炎症性疾病患者的项目。作为回报， 吉利德公司将拥有小分子口服 STAT6 项目的全球开发、生产和商业化权利。\"吉利德科学公司研究执行副总裁弗拉维乌斯-马丁表示：\"通过与LEO Pharma合作，我们希望探索STAT6途径的潜力，为慢性炎症 患者提供一种口服选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","BK4550","BK4578","LU2468319806.SGD","BK4568","IE00BZ1G4Q59.USD","LEO","BK4139","LU2087621335.USD","GILD","BK4583","BK4566","LU1066053197.SGD","BK4585","BK4588","IE00B19Z3581.USD","LU0234570918.USD","LU1839511570.USD","LU0289739699.SGD","LU0109394709.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU1585245621.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU1066051498.USD","LU0889565916.HKD","LU0320765992.SGD","LU1430594728.SGD","LU1571399168.USD","BK4532","IE00B3T34201.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2502525885","title":"大摩：将吉利德科学评级上调至超配","url":"https://stock-news.laohu8.com/highlight/detail?id=2502525885","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502525885?lang=zh_cn&edition=full","pubTime":"2025-01-10 13:23","pubTimestamp":1736486630,"startTime":"0","endTime":"0","summary":"格隆汇1月10日｜摩根士丹利将吉利德科学评级由平配上调至超配，目标价113美元，即上涨27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011013235595fecb29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011013235595fecb29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GILD"],"gpt_icon":0},{"id":"2501728660","title":"更正-更正-加拉帕戈斯公司将分拆创新药物业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2501728660","media":"路透中文","labels":["shareholding","corporation","event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501728660?lang=zh_cn&edition=full","pubTime":"2025-01-08 19:42","pubTimestamp":1736336534,"startTime":"0","endTime":"0","summary":"更新版 3-更正-更正-加拉帕戈斯公司将分拆创新药物业务更新股份，在第 5-7 段和第 9 段增加分析师评论，在第 8 段增加加拉帕戈斯剩余部分的计划Alban Kacher路透1月8日 - 阿姆斯特丹上市制药公司Galapagos GLPG.AS周三表示，该公司计划在2025年中期分拆为两家上市实体，分拆后的业务主要集中在创新药物领域。Galapagos 公司表示，新业务的目标是建立创新药物管线，而 Galapagos 公司的剩余部分将专注于开发肿瘤细胞治疗平台。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nL4T3O40PV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0109394709.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","GILD","BK4550","LU0058720904.USD","BK4588","IE0002270589.USD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","BK4139","LU0320765992.SGD","LU2087621335.USD","BK4578","LU1066051498.USD","IE00B19Z3581.USD","LU1571399168.USD","BK4585","LU0889565916.HKD","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4532","LU1066053197.SGD","BK4583","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1430594728.SGD","BK4568","BK4566","LU1585245621.USD"],"gpt_icon":0},{"id":"2501712986","title":"BUZZ-荷兰医药集团加拉帕戈斯因计划分拆而大涨 11","url":"https://stock-news.laohu8.com/highlight/detail?id=2501712986","media":"路透中文","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501712986?lang=zh_cn&edition=full","pubTime":"2025-01-08 16:19","pubTimestamp":1736324392,"startTime":"0","endTime":"0","summary":"1月8日 -  ** Galapagos GLPG.AS的股票上涨了11%，因为这家荷兰制药公司宣布了 ，计划在今年晚些时候分拆成两个上市实体。** 该集团表示，即将分拆的业务将专注于创新药物，Galapagos 将为其提供约 24.5 亿欧元 现金。** Kempen 分析师认为分拆是积极的，认为这将使 Galapagos \"成为一个更纯粹的生物技术股权故事\"。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nL4S3O40IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B3T34201.USD","LU2087621335.USD","IE00B7SZLL34.SGD","LU1585245621.USD","BK4568","LU2468319806.SGD","BK4588","BK4578","LU0889565916.HKD","BK4583","IE00B19Z3581.USD","LU1839511570.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU0289739699.SGD","LU1430594728.SGD","IE0002270589.USD","BK4532","BK4585","LU0109394709.USD","BK4139","LU0320765992.SGD","IE00BSNM7G36.USD","LU0058720904.USD","IE00BKVL7J92.USD","GILD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1571399168.USD","BK4550"],"gpt_icon":0},{"id":"2500181046","title":"国家医保局将全面推进药品追溯码严监管；吉利德长效HIV疗法在中国获批上市｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2500181046","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500181046?lang=zh_cn&edition=full","pubTime":"2025-01-03 07:59","pubTimestamp":1735862351,"startTime":"0","endTime":"0","summary":"药品追溯码是药品的唯一“电子身份证”。该药品作为处方药上市，将在医院凭医生处方用于治疗相应疾病，为患者提供新的治疗选择。NO.3 吉利德长效HIV疗法在中国获批上市，每年仅需给药两次1月2日，中国国家药监局官网最新公示，吉利德科学公司申报的来那帕韦片和来那帕韦注射液上市申请已获得批准。截至目前，BL-B01D1已有5项适应症被药审中心纳入突破性治疗品种名单。以上适应症分别于2024年5月和7月获得国家药品监督管理局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103080305ab9c692c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103080305ab9c692c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","IE00B3T34201.USD","BK4157","LU2087621335.USD","IE00B7SZLL34.SGD","BMI","LU1585245621.USD","BK4568","LU2468319806.SGD","BK4588","BK4578","LU0889565916.HKD","BK4583","IE00B19Z3581.USD","LU1839511570.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU0289739699.SGD","LU1430594728.SGD","IE0002270589.USD","BK4532","BK4585","LU0109394709.USD","BK4139","LU0320765992.SGD","IE00BSNM7G36.USD","LU0058720904.USD","IE00BKVL7J92.USD","GILD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1571399168.USD","BK4550"],"gpt_icon":0},{"id":"2500413215","title":"医药行业周报：吉利德LENACAPAVIR在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2500413215","media":"太平洋证券股份...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500413215?lang=zh_cn&edition=full","pubTime":"2025-01-03 00:00","pubTimestamp":1735833600,"startTime":"0","endTime":"0","summary":"行业要闻：1 月2 日，中国国家药监局官网公示，吉利德科学申报的5.1类新药来那帕韦片和来那帕韦注射液上市申请已获得批准。来那帕韦是一款HIV-1 衣壳抑制剂，该药已在欧盟、美国等地获批上市，用于联合其他抗逆转录病毒药物治疗多重耐药型HIV 感染成人患者，来那帕韦注射剂只需每半年皮下注射一次。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010311361995f74ddb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010311361995f74ddb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0058720904.USD","LU2468319806.SGD","BK4139","BK4583","GILD","IE00B19Z3581.USD","LU0889565916.HKD","BK4588","BK4550","BK4568","LU1066051498.USD","LU1430594728.SGD","IE00BKVL7J92.USD","LU1585245621.USD","LU2087621335.USD","BK4532","IE00B7SZLL34.SGD","BK4585","IE00BSNM7G36.USD","IE0002270589.USD","BK4566","LU0234570918.USD","LU1066053197.SGD","LU0289739699.SGD","LU1571399168.USD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","BK4578","LU1839511570.USD","IE00B3T34201.USD","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2500264089","title":"吉利德(GILD.US)重磅长效HIV疗法“来那帕韦”在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2500264089","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500264089?lang=zh_cn&edition=full","pubTime":"2025-01-02 21:30","pubTimestamp":1735824601,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月2日，NMPA官网显示，吉利德的HIV疗法来那帕韦钠片及来那帕韦钠注射液的上市申请已获批准。此前该药物已在美国、欧盟等地区获批用于治疗既往接受过多次治疗、多重耐药的HIV-1感染者。那帕韦钠片也仅需每周口服一次。值得一提的是，那帕韦钠在暴露前预防HIV方面也展现了优异的疗效，其针对不同人群的PURPOSE 1研究和PURPOSE 2均已达到了关键疗效终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"吉利德(GILD.US)重磅长效HIV疗法“来那帕韦”在华获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1066051498.USD","LU2468319806.SGD","LU0289739699.SGD","IE00B3T34201.USD","LU0889565916.HKD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4583","LU1839511570.USD","LU0320765992.SGD","BK4585","LU0109394709.USD","LU0058720904.USD","LU1585245621.USD","IE00BKVL7J92.USD","BK4568","LU1571399168.USD","BK4139","BK4578","BK4566","LU0234570918.USD","IE00BZ1G4Q59.USD","BK4550","LU2087621335.USD","IE00B19Z3B42.SGD","GILD","IE0002270589.USD","IE00BSNM7G36.USD","LU1066053197.SGD","LU1430594728.SGD","BK4532","BK4588"],"gpt_icon":0},{"id":"2500994073","title":"国内艾滋病患者迎新药！吉利德HIV长效疗法在华获批，每年仅需给药两次","url":"https://stock-news.laohu8.com/highlight/detail?id=2500994073","media":"时代财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500994073?lang=zh_cn&edition=full","pubTime":"2025-01-02 20:12","pubTimestamp":1735819966,"startTime":"0","endTime":"0","summary":"一款抗HIV新药在华上市。该药物是每年给药两次的HIV长效疗法。但除此以外，迄今为止，艾滋病通过药物治疗仅能抑制HIV病毒，但尚不能治愈。对绝大多数艾滋病患者来说，终身服药才是生活的常态。长效艾滋病药物是为有效地缩短艾滋病患者的服药周期而存在，也在试图解决药物依从性问题。2022年2月1日，美国FDA批准长效HIV注射疗法Cabenuva的新方案，即只需每两个月给药一次。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010220130895f67492&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010220130895f67492&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","GSK.UK","IE00BZ1G4Q59.USD","GILD","LU1066051498.USD","LU1839511570.USD","LU0289739699.SGD","LU1430594728.SGD","LU1585245621.USD","IE00B3T34201.USD","LU1829250122.USD","BK4139","IE00B19Z3B42.SGD","BK4566","BK4550","BK4588","IE00BSNM7G36.USD","LU2468319806.SGD","BK4532","LU0109394709.USD","LU1571399168.USD","GSK","LU2087621335.USD","IE0002270589.USD","BK4007","LU0889565916.HKD","IE00B19Z3581.USD","BK4568","IE00B7SZLL34.SGD","BK4585","IE00BKVL7J92.USD","LU0234570918.USD","LU0320765992.SGD","LU1066053197.SGD","LU0058720904.USD","BK4578"],"gpt_icon":0},{"id":"2500912519","title":"吉利德长效HIV疗法在中国获批上市 每年仅需给药两次","url":"https://stock-news.laohu8.com/highlight/detail?id=2500912519","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500912519?lang=zh_cn&edition=full","pubTime":"2025-01-02 16:53","pubTimestamp":1735808008,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE00B19Z3B42.SGD","BK4566","BK4578","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4585","LU1066053197.SGD","GILD","LU0058720904.USD","BK4550","LU1839511570.USD","LU0289739699.SGD","IE00B3T34201.USD","BK4568","IE00B7SZLL34.SGD","LU1066051498.USD","IE0002270589.USD","LU0234570918.USD","LU1430594728.SGD","BK4532","IE00BKVL7J92.USD","LU2468319806.SGD","BK4588","IE00B19Z3581.USD","BK4139","IE00BSNM7G36.USD","LU1571399168.USD","LU2087621335.USD","LU1585245621.USD","LU0889565916.HKD","LU0320765992.SGD","BK4583"],"gpt_icon":0},{"id":"2500912910","title":"吉利德长效HIV疗法在中国获批上市，每年仅需给药两次","url":"https://stock-news.laohu8.com/highlight/detail?id=2500912910","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500912910?lang=zh_cn&edition=full","pubTime":"2025-01-02 16:25","pubTimestamp":1735806319,"startTime":"0","endTime":"0","summary":"1月2日，中国国家药监局（NMPA）官网最新公示，吉利德科学公司申报的来那帕韦片和来那帕韦注射液上市申请已获得批准。来那帕韦是一款HIV-1衣壳抑制剂，将为对现有疗法无有效应答的HIV感染者提供一种每年仅需给药两次的全新治疗方案。该药此前已在欧盟、美国等地获批上市。（第一财经记者 钱童心）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102162558ab9b8476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102162558ab9b8476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","BK4139","IE00BZ1G4Q59.USD","LU1839511570.USD","LU1066051498.USD","BK4568","LU0289739699.SGD","BK4532","LU0058720904.USD","IE0002270589.USD","GILD","IE00B19Z3B42.SGD","BK4583","BK4585","LU0320765992.SGD","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU1585245621.USD","BK4588","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1571399168.USD","BK4578","BK4550","BK4566","IE00B3T34201.USD","LU1430594728.SGD","LU0234570918.USD","LU1066053197.SGD","IE00BSNM7G36.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2493808780","title":"吉利德科学下跌1.28%，报92.2美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2493808780","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493808780?lang=zh_cn&edition=full","pubTime":"2024-12-24 22:33","pubTimestamp":1735050831,"startTime":"0","endTime":"0","summary":"12月24日，吉利德科学(GILD)开盘下跌1.28%，截至22:33，报92.2美元/股，成交971.08万美元。财务数据显示，截至2024年09月30日，吉利德科学收入总额211.85亿美元，同比增长5.91%；归母净利润-13.03亿美元，同比减少130.76%。大事提醒：2025年2月11日，吉利德科学将于(美东)盘后披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224223833984d84e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224223833984d84e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4578","BK4588","IE00BSNM7G36.USD","BK4585","LU1571399168.USD","LU2087621335.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU0109394709.USD","IE00B19Z3581.USD","LU0058720904.USD","LU1066051498.USD","BK4139","BK4566","LU1066053197.SGD","LU1430594728.SGD","BK4568","IE0002270589.USD","BK4583","LU1839511570.USD","LU0234570918.USD","BK4550","BK4532","IE00BKVL7J92.USD","IE00B3T34201.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B19Z3B42.SGD","LU0289739699.SGD","GILD","IE00BZ1G4Q59.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2492785440","title":"吉利德科学上涨1.23%，报92.21美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492785440","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492785440?lang=zh_cn&edition=full","pubTime":"2024-12-20 23:29","pubTimestamp":1734708572,"startTime":"0","endTime":"0","summary":"12月20日，吉利德科学(GILD)盘中上涨1.23%，截至23:29，报92.21美元/股，成交2.65亿美元。财务数据显示，截至2024年09月30日，吉利德科学收入总额211.85亿美元，同比增长5.91%；归母净利润-13.03亿美元，同比减少130.76%。大事提醒：2025年2月11日，吉利德科学将于(美东)盘后披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220233429a1fe43de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220233429a1fe43de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B3T34201.USD","LU1066053197.SGD","BK4568","LU0289739699.SGD","BK4532","LU0234570918.USD","BK4585","IE00BSNM7G36.USD","BK4550","IE00B19Z3B42.SGD","BK4583","LU0320765992.SGD","IE00B19Z3581.USD","LU1585245621.USD","BK4578","LU1571399168.USD","LU0109394709.USD","LU1066051498.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","GILD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","IE0002270589.USD","LU0889565916.HKD","BK4588","LU2087621335.USD","LU0058720904.USD","LU1839511570.USD","LU1430594728.SGD","BK4139","BK4566"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":0.0363},{"period":"1month","weight":0.0036},{"period":"3month","weight":0.0575},{"period":"6month","weight":0.2732},{"period":"1year","weight":0.0743},{"period":"ytd","weight":0.0001}],"compareEarnings":[{"period":"1week","weight":0.0056},{"period":"1month","weight":-0.0231},{"period":"3month","weight":0.0179},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2481},{"period":"ytd","weight":0.0114}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.039953},{"month":2,"riseRate":0.393939,"avgChangeRate":0.002047},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.009403},{"month":4,"riseRate":0.545455,"avgChangeRate":0.013826},{"month":5,"riseRate":0.545455,"avgChangeRate":0.020012},{"month":6,"riseRate":0.636364,"avgChangeRate":0.026233},{"month":7,"riseRate":0.545455,"avgChangeRate":0.01619},{"month":8,"riseRate":0.545455,"avgChangeRate":0.033979},{"month":9,"riseRate":0.575758,"avgChangeRate":0.032629},{"month":10,"riseRate":0.515152,"avgChangeRate":0.000869},{"month":11,"riseRate":0.636364,"avgChangeRate":0.039409},{"month":12,"riseRate":0.393939,"avgChangeRate":0.011167}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}